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Endothelial Release of Nitric Oxide Contributes 
to the Vasodilator Effect of 
Adenosine in Humans
Paul Smits, Stephen B. Williams, Deborah E. Lipson, Peter Banitt,
Gerard A. Rongen, Mark A. Creager
Background The endogenous nucleoside adenosine plays 
an important role in the regulation o f  vascular tone, especially 
during ischemia. Experimental data derived from animal m od­
els suggest that nitric oxide (NO) contributes to the vasodilator 
effect o f adenosine. The primary purpose of this investigation 
was to determine whether the endothelial release of N O  
contributes to adenosine-induced vasodilation in humans.
Methods and Results Venous occlusion plethysmography 
was used to assess the forearm blood flow (FBF) responses to 
graded intra-arterial infusions of adenosine (1.5 to 500 ju,g/ 
min). Dose-response curves were constructed before and dur­
ing intra-arterial infusion of the N O  synthase inhibitor N a- 
monomethyl-L-arginine (L-NM M A) (2 mg/min, n = 6) or 
vehicle ( n = 6). Before infusion of L-N M M A , adenosine caused  
a d o se -d e p e n d e n t  increase in F B F  from  2.3 to 15.9  
mL • min" 1 • d L '1. During concurrent infusion of L-NM M A, 
adenosine increased FBF from 1.7 to 10.0 mL* m in" 1 *dL_1, 
and this change from baseline was significantly reduced com ­
pared with that before L-NMMA (P < .05). L -N M M A  also 
attenuated the FBF response to adenosine w hen the basal 
constrictor effect o f L-NM M A was prevented by coinfusion of  
the N O  donor sodium nitroprusside ( n = 6, P < t01). In contrast,
L -N M M A  did not affect the FBF response to intra-arterial 
infusion of the endothelium -independent vasodilator verapam­
il (from 2.0 to 13.9 mL • m in"“1 • dL” 1 before L-NM M A and 
from 1.3 to 13.6 mL •m in '"1 * dL ' 1 during L-NMMA; n = 6, 
P = N S ) .  The second objective o f  this study was to determine 
whether the adenosine-induced release of NO is mediated by 
activation of endothelial potassium channels, putadvely cou­
pled to adenosine receptors. Thus, the FBF response to 
adenosine was measured before and during infusion of the 
A TP-dependent potassium channel blocker tolbutamide (1 
mg/min, n - 6), or the potassium channel blocker quinidine (0.5 
mg/min, n = 6). The adenosine-mediated increments in FBF 
were not attenuated by either potassium channel blocker.
Conclusions Adenosine-induced vasodilation in humans is 
mediated, at least in part, by endothelial release of NO. The 
transducing mechanism of this phenomenon is not known, but it 
does not appear to involve the activation of either ATP-depen­
dent or quinidine-sensitive potassium channels. {Circulation, 1995; 
92:2135^2141.)
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A part from its role as a constituent of the intra­cellular energy source ATP, the endogenous nucleoside adenosine also has important ef­fects in the extracellular compartment. In the cardiovas­
cular system, extracellular adenosine is a regulatory 
substance, matching blood flow 'to alterations in tissue 
oxygen supply or demand.1 Until recently, the vasodila­
tor effect of adenosine was thought to be based on direct 
stimulation of A2-adenosine receptors on vascular 
smooth muscle cells, which mediate an increase in the 
second messenger cAMP by stimulating adenylate cy­
clase. Therefore, this agent has been used frequently in 
animal as well as human studies to evaluate endotheli­
um-independent vasodilation.2*3 However, recent inves­
tigations have disputed the endothelium-independent 
character of adenosine-mediated vasodilation. Several
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vascular preparations have shown attenuated responses 
to adenosine or adenosine analogues after previous 
inhibition of endothelial NO synthesis4,5 or after rubbing 
of the endothelium.6“8 Also, infusion of large adenosine 
agonists (M’-octylamine adenosine coupled to carboxy- 
lated latex microspheres), which were assumed to be 
confined to the intravascular space, induced an obvious 
decrease in coronary vascular resistance in the saline- 
perfused guinea pig heart, presumably by means of an 
endothelium-derived mechanism.9 Moreover, functional 
adenosine receptors have been identified on the endo­
thelium, even in human aortic endothelial cells.7
Several potential mechanisms could mediate the en­
dothelial release of NO during adenosine administra­
tion. Stimulation of endothelial adenosine receptors may 
mobilize calcium and thereby activate endothelial NO 
synthase.U) Adenosine A {-receptors have been demon­
strated to be coupled to ATP-dependent potassium 
channels by guanine nucleotide binding proteins, in 
particular by the G«| proteins.11 The Gaj proteins can 
mobilize calcium by stimulating phosphoinositide-spe­
cific phospholipase C activity, causing hydrolysis of 
phosphatidylinositol 4,5-diphosphate.12 Also, adenosine 
can stimulate the endothelial influx of calcium and 
thereby NO synthesis by activating ATP-dependent po­
tassium channels and hyperpolarizing endothelial
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Selected Abbreviations and Acronyms
FBF =  fo rearm  blood flow 
L-NMMA =  À ^-m onom ethyl-L -arg in ine  
NO =  nitric oxide 
SNP =  sodium  nitroprusside
cells.13*14 In addition, potassium channel activation and 
NO release can be triggered nonspecifically by incre­
ments in shear stress related to the raised flow.15
In the present study we evaluated whether the endo­
thelial release of NO plays an im portant role in the 
vasodilating effects of adenosine in humans and, if it 
does, whether the aforementioned potential mecha­
nisms are involved in that NO release. H um an data on 
this subject are especially im portant given the large 
interspecies differences in endothelial pharmacology.16 
To address these questions, the effects of adenosine 
were assessed in vivo by use of the perfused forearm 
technique, both before and during blockade of the 
production of NO by the NO synthase inhibitor 
L-NMMA and before and during blockade of potassium 
channels by the sulfonylurea derivative tolbutamide and 
the antiarrhythmic drug quinidine. These studies, as well 
as appropriate control experiments, allow us to conclude 
that the vascular effects of adenosine in humans are 
based, at least in part, on the endothelial release of NO. 
This adenosine-induced release of NO is not mediated 
by activation of ATP-dependent potassium channels or 
by quinidine-sensitive potassium channels.
Methods
Thirty-nine healthy volunteers participated in the study, and 
all gave written informed consent before participation. The 
health status of each volunteer was determined by medical 
history and a physical examination as well as by laboratory 
investigations to assess lipid levels. Demographic data of the 
participants are shown in Table 1. Subjects who had high blood 
pressure (>145/90 mm Hg) or high concentrations of serum 
cholesterol (LDL greater than the 75th percentile for age and 
sex) or who smoked cigarettes were excluded from participa­
tion because these features can interfere with the NO 
pathway.17'20
Each subject participated in one experiment of approxi­
mately 4 hours5 duration, The experiments were performed in 
a quiet, temperature-controlled room (22°C). The participants 
were all asked to abstain from food, alcohol, and caffeine for at 
least 12 hours before the test. Because caffeine acts as a potent 
adenosine receptor antagonist in the human cardiovascular 
system,21 we measured plasma caffeine levels at the time of the 
test to ensure compliance with respect to the abstinence 
recommendations. The subjects remained in the supine posi­
tion throughout the test. After each subject’s arrival in the 
laboratory, the left brachial artery was cannulated under local 
anesthesia with a 20-gauge catheter, which was used for intra- 
arterial drug infusion as well as for blood pressure monitoring 
(Gould Inc). Drugs were delivered with an automatic syringe 
infusion pump (Harvard Apparatus).
FBF recordings were started after an equilibration period of 
at least 40 minutes. FBF was measured in each arm by venous 
occlusion mercury-in-Silastic stram-gauge plethysmography 
(Hokanson EC4, D.E. Hokanson) as previously described.19 
Both arms rested in slings at heart level, with the forearms 
slightly elevated to ensure a sufficient venous return. To be sure 
that FBF recordings referred predominantly to the forearm 
skeletal muscle circulation, the hand circulation was occluded
during all FBF recordings by a wrist cuff inflated 100 mm Hg 
above the systolic blood pressure.22
Assessment of the Role of NO in the Vasodilator 
Response to Adenosine and Verapamil
In the first subgroup of six subjects, the vasodilator response 
to increasing dosages of adenosine was investigated. Baseline 
measurements were taken during infusion of placebo (glucose 
5%) into the brachial artery. Adenosine was then infused intra- 
arterially in six increasing dosages for 4 minutes per dose 
(adenosine dosages were 1.5, 5, 15, 50, 150, and 500 /¿g/min). 
Measurements were performed during the last 2 minutes of 
each infusion. After an equilibration interval of 60 minutes in 
which the FBF was allowed to return towards baseline levels, 
new baseline recordings were obtained during placebo infu­
sion. Subsequently, infusion of L-NMMA into the brachial 
artery was started at a dose of 2 mg/min. After 15 minutes of 
the L-NMMA-infusion alone, hemodynamic measurements 
were taken to evaluate the vasoactive effects of L-NMMA. 
Thereafter, the six increasing adenosine dosages were again 
administered and coinfused with L-NMMA. The total duration 
of L-NMMA infusion was approximately 40 minutes. In an 
additional series of three subjects, we verified that infusion of 
L-NMMA at 2 mg/min for 40 minutes induced a steady-state 
vasoconstrictor response that did not progress over time.
In the next group of six subjects, similar experiments were 
performed with a similar time schedule and drug dosages of 
adenosine and L-NMMA, but with these experiments the 
L-NMMA infusion was accompanied by a low intra-arterial 
dose of the NO donor SNP. Previous studies have shown that 
L-NMMA infusion induces a vasoconstrictor response in the 
forearm vascular bed by inhibiting the basal release of NO from 
the endothelium.23 From a methodological viewpoint, this 
change in baseline could complicate the interpretation of the 
results, given that the baseline vascular resistance is an impor­
tant determinant of the response to a vasodilator stimulus24 
and that the achieved concentrations of adenosine are propor­
tionally higher in a vasoconstricted state. From pilot studies, we 
determined that an intra-arterial dose of SNP of 0.2 fxg/min 
was appropriate to counteract the vasoconstrictor response to 
L-NMMA. Therefore, this dose of SNP was coinfused with 
L-NMMA. The “clamping” of the NO-mediated vascular tone 
by the concomitant infusion of L-NMMA and SNP has recently 
been shown to be a useful approach in animal experiments on 
this subject.25
An additional six subjects were studied for reasons of time 
control. The same time schedule was used as in the other 
adenosine experiments; however, the second dose-response 
measurement was performed in the presence of placebo in­
stead of active drug. This study was done to ensure that the 
forearm vasodilator response to adenosine did not change over 
the 4-hour experimental session.
In theory, NO release from the endothelium may have been 
triggered nonspecifically by the adenosine-induced increase of 
shear stress resulting from the high FBFs. To evaluate this 
nonspecific stimulus of NO release, we measured FBF re­
sponses to the endothelium-independent calcium entry blocker 
verapamil before and after L-NMMA (2 mg/min) in another six 
subjects. Verapamil was used in four dose-steps of 5 minutes 
each (10, 30, 100, 300 ¡jlg/min). Because verapamil has a longer 
half-life than adenosine, we waited for 90 minutes to wash out 
the drug after the first series of verapamil infusion. Apart from 
these details, the time schedule was similar to that used in the 
previous experiments.
Assessment of the Role of Potassium Channel 
Activation in the Vasodilator Response 
to Adenosine
It recently was shown that adenosine receptors are coupled 
to ATP-dependent potassium channels.11 These channels can 
be blocked specifically by sulfonylurea derivatives, not only in
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the pancreatic j3 cells but also at the level o f  the vessel wall.26 
Therefore, adenosine dose-response studies were performed in 
a fifth group of six volunteers before and during the intrabra- 
chial infusion of tolbutamide ('1 mg/min). The infusion o f  
tolbutamide started 15 minutes before the first adenosine dose. 
Because systemic dosages of tolbutamide may induce hypogly­
cemia by stimulating insulin release and because insulin in­
creases skeletal muscle blood flow and alters vascular respon­
siveness to drugs in the forearm m od el,27-28 arterial blood  
samples for glucose and insulin were taken just before and after 
tolbutamide infusion to demonstrate that no systemic effects 
occurred at this low dose.
In an additional six healthy volunteers, the vascular response 
to adenosine was assessed before and during the intra-arterial 
infusion of 0.5 mg/min quinidine. Studies have shown by use of  
the patch-clamp technique that quinidine blocks several types 
of potassium channels,29'33 including those activated by aden­
osine. To limit the cumulative dose o f  quinidine in healthy 
volunteers, we used only the four highest adenosine dosages 
(instead of all six) in these subjects. M easurem ents o f FBF and 
subsequent administration of  the four adenosine dosages were 
started after 10 minutes o f quinidine infusion, and the total 
infusion time of quinidine was restricted to 30 minutes (cumu­
lative dose, 15 mg).
Drugs
A denosine was prepared for each experiment by dilution of  
Adenocard vials (6 mg per 2 mL, Fujisawa Pharmaceutical Co) 
in saline. A^-monomethyl-L-arginine acetate, purchased from 
Calbiochem, was diluted in glucose 5%  just before the exper­
iments. SNP was purchased from Elkins-Sinn, Inc. Protected  
from light, it was dissolved in glucose 5% just before adminis­
tration. Verapamil HC1 (American R eagent Laboratories Inc) 
was diluted with glucose 5%. For the tolbutamide experiments, 
sterile tolbutamide sodium (Orinase Diagnostic, T he Upjohn  
Co) was dissolved in saline (NaCl 0.9%). For the quinidine 
studies, we used quinidine gluconate vials (Eli Lilly) of 800 
mg/10 mL diluted in glucose 5%. D epending on the experi­
m ent, glucose 5%  or saline was used as placebo infusion. All 
drugs and placebo infusions were administered at the same  
infusion rate o f 0.4 mL/min.
Statistics and Calculations
T he effects o f  adenosine were analyzed by comparison of the 
hemodynamic variables at baseline and at the six dosage levels 
by one-way A N O V A  with repeated measures. Post hoc com ­
parisons between the different dosages were m ade by Scheffe’s 
F  tests. The paired t test was used for the assessment of the 
effects o f L-NM M A, tolbutamide, or quinidine on baseline 
parameters. To evaluate the effect o f  the intervention (N O  
synthase blockade, potassium channel blockade) on the aden­
osine or verapamil responses, two-way repeated-measures 
A N O V A  was performed on the changes from baseline. B e ­
cause the mean arterial blood pressure was not affected by 
either drug infusion (see “Results”), FBF changes were as­
sumed to represent changes in forearm vascular tone. Differ­
ences were considered to be statistically significant at P c .0 5  
(two-tailed). All results are presented as m ea n ± S E M  unless 
otherwise indicated.
Results
Vasodilator Response to Adenosine
For assessment of the vascular response to graded 
adenosine infusion, the data of the first dose-response 
curve for all experiments with the six adenosine dosages 
were pooled (n -2 4 ). Table 2 summarizes the results of 
this analysis. Adenosine induced a dose-dependent in­
crease in FBF, which was significantly different from 
baseline for the third through sixth dosage levels. The 
dose dependency was supported by significant differ­
ences between dosages (Scheffé’s F  tests, Pc.05). One 
hour after cessation of adenosine infusion, the FBF was 
identical to the baseline level. As shown in Table 2, there 
were no changes in flow in the noninfused forearm or in 
blood pressure or heart rate during adenosine infusion, 
arguing against any systemic effect of the dosages used. 
In the subset of experiments in which the adenosine 
infusions were repeated after 1 hour without any inter­
vention (time controls), adenosine increased FBF the first 
time from 2.3±0.4 to 15.2±4.7 m L 'm in '1 «dL“1 and the 
second time from 1.9±0,7 to 16.0±7.2 mL*min”1 • dL"1. 
There was no significant difference between the FBF 
changes from baseline between the first and second series 
of measurements.
Plasma caffeine levels could not be detected in 20 of 
23 subjects in whom it was measured (lower limit of 
assay, 0.5 mg/L). In the remaining three subjects, caf­
feine concentration ranged from 1.8 to 4.0 mg/L. Despite 
detectable caffeine levels in these three subjects, each 
showed a vasodilator response to adenosine that was 
comparable to that observed in the others, justifying 
inclusion of their data in the results. Moreover, statisti­
cal analysis after exclusion of these subjects did not 
affect the outcome of the findings.
Vasoconstrictor Response to L-NMMA
To assess the effect of L-NMMA on basal FBF, the 
data from six L-NMMA-adenosine experiments, three 
L-NMMA time-control experiments, and six L-NMMA- 
verapamil experiments were pooled. After 15 minutes of 
intra-arterial L-NMMA infusion, FBF decreased signif­
icantly from 2.1±0.2 to 1.5±0.1 m L , m in’*1 -d L "1 
( n - 1 5 ,  paired t test: jPc.O'I). In contrast, the FBF of 
the contralateral noninfused arm remained constant 
during this infusion (1.8±0.1 before and 1.8±0.1 
mL ■ m in "L * dL“1 during L-NMMA infusion). M ore­
over, L-NM M A infusion did not change the mean 
arterial blood pressure (81.3±2.3 versus 79.1 ±2.7 
mm Hg, P = N S ) or heart rate (56.1 ±2 .2  versus 
54.9 ±2.1 beats per minute, P=NS), indicating that 
locai L-NM M A infusion did not affect systemic hemo­
dynamics. In the three subjects in whom L-NMMA 
was the only drug given, the FBF fell from 1.8±0.3 
m L • m u T 1 ■ dL "1 at baseline to 1.3±0.2 and 1.6±0.1 
m L * m in “1 • dL~! after 15 and 40 minutes, respec­
tively, arguing against a progressive vasoconstrictor 
effect after 15 minutes of infusion.
Effects of NO Synthase Blockade on 
Vasodilator Responses
Fig 1 illustrates the FBF response to the six increasing 
adenosine dosages during the placebo and L-NMMA 
infusions. Adenosine in the presence of placebo induced 
a dose-dependent increase in FBF from 2.3±0.2 to 
15.9±3.1 mL • min“1 ■ dL“1. During coinfusion with 
L-NMMA, adenosine increased FBF from 1.7 to 10.0 
mL ‘ min’ 3 • dL“' , this response being significantly reduced 
compared with the first dose-response curve. The concom­
itant infusion of L-NMMA and adenosine elicited no 
significant changes in contralateral FBF (from 1.8 ±0.2 
mL • min-1 • dL“1 at baseline to 2.3±0.3 mL * min“1 * dL"1 
at the highest adenosine dose), mean arterial pressure 
(from 80±4 to 83±4 mm Iig), or heart rate (from 55±2 to 
54±2 beats per minute).
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Forearm blood flow (ml/min/dl)
Base 1.5 5 15 50 150 500
Adenosine dose (jxg/min)
Fig 1. Graph shows FBF response to graded intra-arterial 
adenosine infusion in the presence of placebo (■) and during 
concomitant infusion of L-NMMA (o). Values are shown as 
mean±SEM. P<.05 for the difference between conditions for 
these dose responses by repeated-measures ANOVA.
In the second series of experiments, the vasoconstric­
tor effect of L-NMMA was counteracted by concomitant 
infusion of SNP. Again, in the presence of placebo, 
adenosine caused a dose-dependent forearm  vasodilator 
effect with an increase of FBF from 1.9±0.4 to 14.9±2.0 
mL*min~J ■ dL"1 (Fig 2). A fter conditions returned to 
baseline, the combined infusion of L-NM M A and SNP 
did not significantly change FBF (2.0±0.3 versus 2.2±0.3 
mL • m in"1 ■ dL"1; n=6, P = N S ). The subsequent admin­
istration of the six adenosine dosages elicited dose- 
dependent increments in FBF from 2.2±0.3 to 9.8±2,4 
mL • min"1 • dL“1; the changes from baseline were signifi­
cantly reduced compared with those before administration 
of L-NMMA and SNP (Pc.01) (Fig 2). No significant 
changes occurred in contralateral FBF (from. 1.7 ±0,3 
mL ■ min-1 • dL"1 at baseline to L8±0.3 mL ■ min“1 - dL“1 
at the highest adenosine dose), mean arterial pressure 
(from 7 9 ± 4 to 8 1 ± 3  mm Hg), or heart rate (from 53±2 to 
53±3 beats per minute).
Forearm blood flow (ml/min/dl)
Base 1.5 5 15 50 150 500
Adenosine dose (|lg/min)
Fig 2. Graph shows FBF response to graded intra-arterial 
adenosine infusion in the presence of placebo (■) and during the 
combined infusion of L-NMMA and SNP (L-NMMA+SNP, o). 
Values are shown as mean±SEM. P<.01 for the difference 
between conditions for these dose responses by repeated- 
measures ANOVA.
Forearm blood flow (ml/min/dl)
Adenosine dose Qig/min)
Fig 3. Graph shows FBF response to graded intra-arterial 
adenosine infusion in the presence of placebo (■) and during 
concomitant infusion of the potassium channel blocker tolbut­
amide (o). Values are shown as mean±SEM. There were no 
significant differences in the dose-response relation between 
placebo and tolbutamide as analyzed by repeated-measures 
ANOVA.
The intra-arterial infusion o f L-NM M A did not 
change the forearm vasodilator response to verapamil. 
During placebo, the FBF changes from baseline for the 
four increasing verapamil dosages averaged 2.3±0.5, 
4.2±0.7, 8 .6±1.9, and 11.9±2.8 mL * m in“1 * dL“1, 
whereas these numbers were 1.7±0.2, 3.5±0.9, 6.7±1.4, 
and 12.2±2.4 mL • m in“1 • d L "1 during concomitant 
L-NM M A administration. No significant effects on sys­
temic hemodynamics were observed during the com­
bined infusion of L-NM M A and verapamil. The con­
tralateral FBF was 1.9±0.2 mL • m in”1 * dL ”1 before and 
1.6±0.3 m L ’ m in”1 * dL-1 during the highest verapamil 
dose. Respective values for mean arterial blood pressure 
were 79±2 and 79± 2  mm Fig, and for heart rate they 
were 56± 4  and 58± 4  beats per minute.
Effects of Potassium Channel Blockade on 
Adenosine Responses
Fig 3 demonstrates the effects of tolbutamide on the 
vasodilator response to adenosine. Tolbutamide infusion 
into the brachial arteiy did not change the baseline FBF 
(2.3±0.3 versus 2.2±0.3 m L • m in"1 • dL "1). Moreover, 
the adenosine-induced increase in FBF was not reduced 
by tolbutamide.
Fig 4 illustrates the effects of quinidine on the forearm 
vasodilator response to adenosine infusion. In this se­
ries, adenosine increased FBF from 1.6±0.3 to 9.0±0.8 
mL* m in“1 • dL“1. After equilibration, the FBF returned 
to a baseline value of 1.5 m L * m in"1 * d L " T e n  minutes 
of quinidine infusion increased the baseline FBF signif­
icantly to 2.9±0,7 m L 'm in " 1 ■ dL “1 (P<.05). However, 
regional quinidine infusion did not significantly affect 
the adenosine-induced increase in FBF from baseline.
Throughout these two series of experiments, there 
were no changes in contralateral FBF, blood pressure, or 
heart rate. The plasma insulin concentrations averaged 
4.4 ±1.2 ¿¿U/mL before and 4.5 ±1.2 juAJ/mL after tolbu­
tamide administration (P=N S), and the glucose levels 
were 84±3 and 81 ± 2  mg/dL, respectively (P=NS).
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Fig 4. Graph shows FBF response to graded intra-arterial 
adenosine infusion in the presence of placebo (■) and during 
concomitant infusion of the potassium channel blocker quinidine 
(o). Values are shown as m ean±SEM . There were no significant 
differences in the dose-response relation between placebo and 
quinidine as analyzed by repeated-measures ANOVA,
Discussion
The results of this study enable us to conclude that the 
vasodilator response to adenosine in humans is medi­
ated, at least in part, by the endothelial release of NO, 
The following evidence supports this conclusion: (1) 
blockade of NO synthase by L-NMMA significantly 
reduced the FBF response to adenosine, (2) the vehicle- 
control experiments ensured that this reduced response 
could not be attributed to time; and (3) the observation 
that L-NMMA attenuated adenosine responses could 
not be attributed to a change in basal vascular resistance, 
because restoration of baseline conditions by the addi­
tion of a low dose of SNP did not change the results. We 
reasoned that the coinfusion of SNP and L-NMMA was 
the most ideal approach to correct for the L-NM M A- 
associated change in baseline vascular resistance. Addi­
tion of exogenous NO by infusion of SNP was thought to 
restore the baseline biology of the vascular wall and 
recondition its responsiveness to vasoactive stimuli.25 
Also, the vasoconstrictor effect of L-NMMA (when 
infused alone) did not progress over time and thus could 
not account for the L-NMMA-mediated reduction in 
adenosine responses. Apart from the pathophysiological 
consequences of our conclusion, it is obvious that the use 
of adenosine for the assessment of endothelium-inde- 
pendent vasodilation in peripheral resistance vessels is 
not a valid approach in human research.
Several recent studies in animals support our obser­
vations,4’5’8’34 but others do not.2*35 Species differences 
and different experimental conditions may contribute to 
this discrepancy. In the perfused-fore arm technique 
used in this study, the drug is administered into the 
vascular lumen, so the exposure to adenosine is much 
higher for the vascular endothelium than for the under­
lying smooth muscle cell layer, especially because of the 
efficient uptake of adenosine by the endothelium.36*37 In 
several in vitro vascular preparations, the exposure is 
more balanced, and therefore direct relaxant effects on 
smooth muscle cells mediated by stimulation of A 2-aden- 
osine receptors may have been more pronounced.37
Shear Stress as a Mechanism of Action
A  number of transducing mechanisms should be con­
sidered as mediators for the ability of adenosine to 
release endothelium-derived NO. For example, the aden­
osine-induced release of NO might have been triggered 
nonspecifically by the increase in flow (shear stress) 
ra ther than by the specific stimulation of endothelial 
adenosine receptors. However, in previous studies in 
which the same technique was used, the intra-arterial 
infusion of L-NMMA reduced the relaxant effects of 
acetylcholine but not those of SNP, arguing against a 
contribution of flow-related NO release during drug- 
induced elevations of FBF.38 Furthermore, in the pres­
ent study, L-NMMA did not attenuate the vasodilator 
response to the calcium entry blocker verapamil, an 
endothelium-independent vasodilator, despite produc­
tion of blood flow responses comparable to those ob­
served in the middle of the dosage range of adenosine. 
O ur data therefore point toward a more specific inter­
action between L-NMMA and adenosine. We and oth­
ers previously showed that low intrabrachial dosages of 
the adenosine receptor antagonists caffeine and theo­
phylline are able to block the forearm vasodilator re­
sponse to adenosine,21*39 enabling us to postulate that 
the adenosine-mediated release of NO results from 
stimulation of endothelial adenosine receptors. Unfor­
tunately, selective agonists and antagonists for the dif­
ferent subtypes of adenosine receptors are not available 
for human use, so it is not possible at this time to 
determine whether the adenosine-induced NO release in 
humans is mediated by stimulation of endothelial A r  or 
A 2“adenosine receptors.
Role of Potassium Channels
We postulated that activation of potassium channels 
may serve as an intermediate step, transducing stimula­
tion of adenosine receptors to the synthesis and/or 
release of NO from the endothelium. Because equipo- 
tent dosages of the related sulfonylurea derivative glib- 
enclamide have been shown to attenuate the vasodilator 
response to pharmacological opening of KATP channels 
in the forearm vascular bed,40*41 we think that our 
negative observation of tolbutamide cannot be attrib­
uted to ineffective dosing. Consequently, our data sup­
port the conclusion that opening of the KATP channel 
does not contribute to the vasodilator response to intra- 
arterial adenosine infusion in humans. In theory, KATP 
channel opening might have contributed to the vasoac­
tive effects of adenosine at two different levels. At the 
level of the endothelium, KATP channel opening may 
hyperpolarize endothelial cells, and may thereby activate 
endothelial NO release by increasing the influx of calci­
um.42 In contrast to increases of calcium influx in 
endothelial cells after hyperpolarization, calcium influx 
decreases after membrane hyperpolarization in vascular 
smooth muscle cells.42 Therefore, opening of potassium 
channels also results in vasodilation at the level of 
vascular smooth muscle cells. It must be emphasized that 
because of our intraluminal administration of adenosine, 
its effects may have been predominantly endothelium 
dependent, and therefore we think that our tolbutamide 
data do not exclude a role of KATp channel activation in 
the smooth muscle-relaxing effects of adenosine.
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Although we realize that quinidine has several phar­
macological properties, including sodium channel block­
ade and antiadrenergic effects, its recently established 
potassium channel-blocking properties made this drug 
an additional tool for our study, especially because 
quinidine was able to attenuate the vasodilator response 
to adenosine in animal studies.43 Quinidine increased 
basal FBF but did not attenuate the vasodilator response 
to adenosine. The effect of quinidine on the baseline 
flow may well be explained by its a-adrenergic-blocking 
properties. In line with the reasoning on tolbutamide, 
our data argue against a role of quinidine-sensitive 
potassium channels in the adenosine-mediated release 
of NO but do not exclude an interaction between 
quinidine and adenosine at the level of vascular smooth 
muscle cells.
Pathophysiological Implications
Apart from effects on vascular tone, adenosine has 
other important properties, including inhibition of plate­
let aggregation,44 inhibition of leukocyte activation,45 
and presynaptic inhibition of noradrenaline release.46 
Furthermore, adenosine appears to mediate ischemic 
preconditioning in the myocardium.47 The release of 
endogenous adenosine may also contribute to the reac­
tive hyperemic response after ischemia14*48 as well as to 
exercise-induced vasodilation.49 In recent years, NO has 
been demonstrated to affect several of these pathophys­
iological phenomena in a similar way.14’48’50'53 Because 
adenosine is released from tissues, including the endo­
thelium, during anoxia or ischemia,54 the currently ob­
served relation between adenosine and endothelial NO 
release makes endogenous adenosine a likely candidate 
for triggering NO release during ischemia. W e believe 
that our results create the foundation for future studies 
on the interrelation between the release of endogenous 
adenosine and that of NO in several pathophysiological 
conditions in humans.
Acknowledgments
This research was supported by an NIH program project 
grant in vascular biology and medicine (HL-4S743). M.A.C. is 
a recipient of an NHLBI academic award in systemic and 
pulmonary vascular medicine (HL-02663). The authors grate­
fully acknowledge Joanne Normandin for manuscript 
preparation.
References
1. Olsson RA, Bunger R. Metabolic control of coronary blood flow. 
Prog Cardiovcisc Dis. 1987;29:369-387.
2. White DG, Drew GM, Gurden JM, Penny DM, Roach AG, Watts
IS, The effect of NG-nitro-L-arginine methyl ester upon basal blood 
flow and endothelium-dependent vasodilation in the dog hindlimb. 
BrJ Pharmacol 1993;108:763-768.
3. Treasure CB, Vita JA, Cox DA, Fish D, Gordon JB, Mudge GH, 
Colucci WS, St John Sutton MG» Selwijn AP, Alexander RW, Ganz 
P. Endothelium-dependent dilation of the coronary microvascu- 
lature is impaired in dilated cardiomyopathy. Circulation. 1990;81: 
772-779,
4. Vials A, Burnstock G. A2-purinaceptar-mediated relaxation in the 
guinea-pig coronary vasculature: a role for nitric oxide. Br J 
Pharmacol. 1993;109:424-429.
5. Okamura M, Miura K, Yamashita Y, Yukimura T, Yamamoto K. 
Role of endothelium-derived relaxing factor in the in vivo renal 
vascular action of adenosine in dogs. J Exp Pharmacol Ther. 1992; 
260:1262-1267.
6. Headrick JP, Berne RM. Endothelium-dependent and 
-independent relaxations to adenosine in guinea pig aorta. Am J
Physiol 1990;259:H62-H67.
7. Iwamoto T, Umemura S, Toya Y, et al. Identification of adenosine 
A2 receptor-cAMP system in human aortic endothelial cells. 
Biochem Biophys Res Commun. 1994;199:905-910.
8. Rose*Meyer RB, Hope W. Evidence that A2-purinoceptors are 
involved in endothelium-dependent relaxation of the rat thoracic 
aorta. Br J Phannacol. 1990;100:576-580.
9. Balcells E, Suarez J, Rubio R. Functional role of intravascular 
coronary endothelial adenosine receptors. Ear J Phannacol. 1992; 
210:1-9.
10. Moncada S. Nitric oxide: physiology, pathophysiology and pharma­
cology. Pharmacol Rev. 1991;43:109-142.
11. Kirsch GE, Codina J, Birnbaumer L, Brown AM. Coupling of 
ATP-sensitive K-channels to Al-receptors by G proteins in rat 
ventricular myocytes. Am J Physiol. 1990;259:H820-H826.
12. Liao JK, Homey CJ, The G proteins of the G a( and Ga4 family 
couple the bradykinin receptor to the release of endothelium- 
derived relaxing factor. J Clin Invest. 1993;92:2168-2172.
13. Seiss-Geuder M, Mehrke G, Daut J. Sustained hyperpolarization of 
cultured guinea pig coronary endothelial cells induced by adeno­
sine. J Cardiovasc Pharmacol 1992;20(suppl 12):S97-S100.
14. Leipert B, Becker BF, Gerlach E. Different endothelial mech­
anisms involved in coronary responses to known vasodilators. Am J 
Physiol 1992;262:H1676-H1683.
15. Cooke JP, Rossitch E, Andon NA, Loscalzo J, Dzau VJ. Flow 
activates an endothelial potassium channel to release an endoge­
nous nitrovasodilator, J Clin Invest, 1991;88:1663-1671.
16. Liischer TF, Vanhoutte PM. Endothelium-dependent responses in 
human blood vessels: human versus animals. Trends Pharmacol Sci.
1988;9:181-184.
17. Kiowski W, Linder L, Stoschitzky K, et al. Diminished vascular 
response to inhibition of endothelium-derived nitric oxide and 
enhanced vasoconstriction to exogenously administered 
endothelin-1 in clinically healthy smokers. Circulation. 1994;90: 
27-34.
18. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endo­
thelium-dependent vascular relaxation in patients with essential 
hypertension. N  Engl J Med, 1990;323:22-27,
19. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, 
Cooke JP. L-Arginine improves endothelium-dependent vasodi­
lation in hypercholesterolemic patients. J Clin Invest. 1992;90: 
1248-1253.
20. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, 
Cannon RO III. Selective loss of microvascular endothelial 
function in human hypercholesterolemia. Circulation, 1994;90: 
35-41.
21. Smits P, Lenders JWM, Thien T. Caffeine and theophylline 
attenuate adenosine-induced vasodilation in humans. Clin 
Pharmacol Ther. 1990;48:410-418.
22. Lenders J, Janssen G-J, Smits P, Thien T. Role of the wrist cuff in 
forearm plethysmography. Clin Sci. 1991;80:413-417.
23. Vallance PCJ, Moncada S. Effects of endothelium-derived nitric 
oxide on peripheral arteriolar tone in man. Lancet. 1989;2: 
997-1000.
24. Myers HA, Honig CR. Influence of initial resistance on magnitude 
of response to vasomotor stimuli Am J Physiol. 1969;216:1429-1436.
25. Koller A, Sun D, Huang A, Kaley G. Corelease of nitric oxide and 
prostaglandins mediates flow-dependent dilation of rat gracilis 
muscle arterioles. Am J Physiol. 1994;267:H326-H332.
26. Meisheri KD, Khan SA, Martin JL. Vascular pharmacology of 
ATP-sensitive K-channels: interactions between glyburide and 
K-channel-openers. I Vase Res. 1993;30:2-12.
27. Anderson EA, Mark AL. The vasodilator action of insulin: impli­
cations for the insulin hypothesis of hypertension. Hypertension. 
1993;21:136-141.
28. Lembo G, Rendina V, Iaccarino G, Lamenza F, Volpe M, Trimarco
B. Insulin reduces reflex forearm sympathetic vasoconstriction in 
healthy humans. Hypertension. 1993;21:1015-1019,
29. Benz I, Kohlhardt M. Blockade of cardiac outwardly rectifying 
K-channels by TEA and class III antiarrhythmics: evidence against 
a single drug-sensitive channel site. Eur Biophys J, 1994;22:437-446.
30. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient 
outward current in cardiac muscle. Am J Physiol 1987;253: 
H704-H708.
31. Richards NW, Dawson DC. Single potassium channels blocked by 
lidocaine and quinidine in isolated turtle colon epithelial cells. Am 
J Physiol 1986;251:C85-C89.
32. Salata JJ, Wasserstrom JA. Effects of quinidine on action potentials 
and ionic currents in isolated canine ventricular myocytes. Circ Res.
1988;62:324-337.
Smits et al Adenosine and Endothelial NO Release 2141
33. Roden DM, Bennett PB, Snyders DJ, Baiser JR, Hondeghem LM. 
Quinidine delays Ik-activation in guinea pig ventricular myocytes.
CircRes, 1988;62:1055-1058,
34. Read MA, Boura ARA, Walters WAW, Vascular action of purines 
in the foetal circulation of the human placenta. Br J Pharmacol.
1993;110:454-460.
35. Kirkeboen KA, Naess PA, Offstad J, Ilebekk A, Effects of regional 
inhibition of nitric oxide synthesis in intact porcine hearts, Am J 
Physiol, 1994;266:H1516-H1527.
36. Nees S, Herzog V, Becker BF, Bock M, Des Rosier CEG. The 
coronary endothelium: a highly active metabolic barrier for aden­
osine. Basic Res Carcliol. 1985;80:515-529.
37. Headrick JP, Northington FJ, Hynes MR, Mather ne GP, Berne 
RM. Relative responses to luminal and adventitial adenosine in 
perfused arteries. Am J Physiol. 1992;263:H1437-H1446.
38. Rongen G, Smits P, Thien TH. Characterization of ATP-induced 
vasodilation in the human forearm vascular bed. Circulation. 1994; 
90:1891-1898.
39. Taddei S, Pedrinelli R, Salvetti A. Theophylline is an antagonist of 
adenosine in human forearm arterioles. Am J Hypertens. 1991;4: 
256-259.
40. Ashcroft SJH, Ashcroft FM. Properties and functions of ATP- 
sensitive potassium channels. Cell Signal. 1990;2:197-214,
41. Bijlstra PJ, Smits P, Lutterman JA, Thien TH. Glibenclamide 
inhibits the vasodilator effect of potassium channel activation in 
man. Diabetologia. 1994;37(suppl i):AI62, Abstract.
42. Janigro D, West GA, Gorden EL, Winn HR. ATP-sensitive 
K+-channels in rat aorta and brain microvascular endothelial cells. 
A m  J Physiol. 1993;265:C812-C821.
43. Burnstock G. Purinergic nerves, Pharmacol Rev. 1972;24:509-581.
44. Edlund A, Siden Ä, Sollevi A. Evidence for an anti-aggregate ry 
effect of adenosine at physiological concentrations and for its role 
in the action of dipyridamole. Thromb Res, 1987;45:183-190,
45. Cronstein BC, Levin RI, Belanoff J, Weissmann G, Hirschhom R. 
Adenosine: an endogenous inhibitor of neutrophil-mediated injury 
to endothelial cells. I  Clin Invest, 1986;78:760-770.
46. Wennmalm M, Fredholm BB, Hedqvist P. Adenosine as a mod­
ulator of sympathetic nerve-stimulation-induced release of nor­
adrenaline from the isolated rabbit heart. Acta Physiol Scand. 1988; 
132:487-494.
47. Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J. Myo­
cardial protective effects of adenosine: infarct size reduction with 
pretreatment and continued receptor stimulation during ischemia. 
Circulation. 1992;86:986-994,
48. Maekawa K, Saito D, Obayashi N, Uchida S, Haraoka S. Role of 
endothelium-derived nitric oxide and adenosine in functional myo­
cardial hyperemia. Am I  Physiol. 1994;267:H166-H173.
49. Goonewardene IP, Karim F, Attenuation of exercise-induced vaso­
dilation by adenosine deaminase in anaesthetized dogs. J Physiol. 
1991;442:65-79.
50. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an 
endothelial cell relaxation factor, inhibits neutrophil superoxide 
anion production via a direct action on the NADPH oxidase. J Clin 
Invest. 1992;90:1116-1121.
51. Siegfried MR, Erhardt J, Rider T, Ma XL, Lefer AM. Cardiopro- 
tection and attenuation of endothelial dysfunction by organic nitric 
oxide donors in myocardial ischemia-reperfusion. I Pharmacol Exp 
Ther. 1992;260:668-675.
52. Vegh A, Szekeres L, Parratt J. Preconditioning of the ischaemic 
myocardium: involvement of the L-arginine nitric oxide pathway. Br 
J Pharmacol. 1992;107:648-652.
53. Loscalzo J, Vita JA. Ischemia, hyperemia, exercise, and nitric oxide: 
complex physiology and complex molecular adaptations. 
Circulation. 1994;90:2556-2559.
54. Smolenski RT, Kochan Z, McDouall R, Page C, Seymour A-ML, 
Yacoub MH. Endothelial nucleotide catabolism and adenosine pro­
duction. CanUovasc Res. 1994;28:100-104.
